| Jeffrey M Thomas, APN | |
|
849 W State St, Trenton, NJ 08618-5325 | |
| (732) 668-6196 | |
| (609) 739-8926 |
| Full Name | Jeffrey M Thomas |
|---|---|
| Gender | Male |
| Speciality | Nurse Practitioner |
| Location | 849 W State St, Trenton, New Jersey |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134643323 | NPI | - | NPPES |
| Entity Name | Pegasus Emergency Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336179621 PECOS PAC ID: 5890789176 Enrollment ID: O20040409000575 |
News Archive
A microscope about the size of a penny is giving scientists a new window into the everyday activity of cells within the spinal cord. The innovative technology revealed that astrocytes-cells in the nervous system that do not conduct electrical signals and were traditionally viewed as merely supportive-unexpectedly react to intense sensation.
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Baxter Healthcare Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a new 3000 IU (5mL) dosage strength of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method].
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
› Verified 3 days ago
| Entity Name | Hampton Family Practice, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578792040 PECOS PAC ID: 7719033794 Enrollment ID: O20090916000114 |
News Archive
A microscope about the size of a penny is giving scientists a new window into the everyday activity of cells within the spinal cord. The innovative technology revealed that astrocytes-cells in the nervous system that do not conduct electrical signals and were traditionally viewed as merely supportive-unexpectedly react to intense sensation.
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Baxter Healthcare Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a new 3000 IU (5mL) dosage strength of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method].
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
› Verified 3 days ago
| Entity Name | Hunterdon Urgent Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154791796 PECOS PAC ID: 9638460876 Enrollment ID: O20160620001504 |
News Archive
A microscope about the size of a penny is giving scientists a new window into the everyday activity of cells within the spinal cord. The innovative technology revealed that astrocytes-cells in the nervous system that do not conduct electrical signals and were traditionally viewed as merely supportive-unexpectedly react to intense sensation.
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Baxter Healthcare Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a new 3000 IU (5mL) dosage strength of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method].
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
› Verified 3 days ago
| Entity Name | Ars Treatment Centers Of New Jersey Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720644800 PECOS PAC ID: 4587994397 Enrollment ID: O20190920002654 |
News Archive
A microscope about the size of a penny is giving scientists a new window into the everyday activity of cells within the spinal cord. The innovative technology revealed that astrocytes-cells in the nervous system that do not conduct electrical signals and were traditionally viewed as merely supportive-unexpectedly react to intense sensation.
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Baxter Healthcare Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a new 3000 IU (5mL) dosage strength of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method].
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey M Thomas, APN 849 W State St, Trenton, NJ 08618-5325 Ph: (732) 668-6196 | Jeffrey M Thomas, APN 849 W State St, Trenton, NJ 08618-5325 Ph: (732) 668-6196 |
News Archive
A microscope about the size of a penny is giving scientists a new window into the everyday activity of cells within the spinal cord. The innovative technology revealed that astrocytes-cells in the nervous system that do not conduct electrical signals and were traditionally viewed as merely supportive-unexpectedly react to intense sensation.
Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal hormone therapy may actually lower the risk of B-cell non-Hodgkin lymphoma.
Baxter Healthcare Corporation announced that the U.S. Food and Drug Administration (FDA) has approved a new 3000 IU (5mL) dosage strength of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method].
Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced that it has granted Novartis an option to obtain an exclusive worldwide license to develop and commercialize its p53 temporary inhibitor siRNA drug QPI-1002, currently the subject of a Phase II clinical trial.
› Verified 3 days ago
Gina Novilus, NP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: Po Box 5953, Trenton, NJ 08638 Phone: 609-278-8994 | |
Frances Mary Herman, APRN,BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 601 Hamilton Ave, Trenton, NJ 08629 Phone: 606-599-5353 Fax: 609-599-5799 | |
Ashleigh Elizabeth Linkenheimer, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 750 Brunswick Ave, Trenton, NJ 08638 Phone: 609-894-6000 | |
Ms. Katharine Elizabeth Donaldson, APN,C,MSN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 446 Bellevue Ave, Trenton, NJ 08618 Phone: 609-394-4382 | |
Ms. Tamara Melendez, NP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 750 Brunswick Ave, Trenton, NJ 08638 Phone: 609-394-6000 | |
David Shamer, MSN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 601 Hamilton Ave, Trenton, NJ 08629 Phone: 856-220-8891 | |
Alison Panno, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 750 Brunswick Ave, Trenton, NJ 08638 Phone: 609-394-6000 |